Abstract: A terahertz radiator is based on coherent Smith-Purcell radiation amplified by stimulation. The terahertz radiator includes an electron emission source configured to emit electron beams and a pumping source configured to emit pumping signals. The pumping signal interacts with a primary grating structure to obtain preliminarily bunched electrons. The preliminarily bunched electrons interact with the primary grating structure to generate coherent Smith-Purcell radiation. The coherent Smith-Purcell radiation and the pumping signals vertically resonate in a primary resonant cavity structure, so that the electron bunching density is increased, and in turn, the coherent Smith-Purcell radiation is enhanced. A positive feedback process is formed by free electrons and the coherent Smith-Purcell radiation, and the coherent Smith-Purcell radiation amplified by stimulation and periodic bunched electron bunches are obtained.

Abstract: Representative embodiments disclose machine learning classifiers used in scenarios such as speech recognition, image captioning, machine translation, or other sequence-to-sequence embodiments. The machine learning classifiers have a plurality of time layers, each layer having a time processing block and a depth processing block. The time processing block is a recurrent neural network such as a Long Short Term Memory (LSTM) network. The depth processing blocks can be an LSTM network, a gated Deep Neural Network (DNN) or a maxout DNN. The depth processing blocks account for the hidden states of each time layer and uses summarized layer information for final input signal feature classification. An attention layer can also be used between the top depth processing block and the output layer.

Abstract: A method for controlling a suspension system is disclosed. The method includes obtaining a first group of signals and a second group of signals; determining whether a trigger condition is met; determining an adjustment signal for adjusting the suspension system based on related signals of the suspension system, in response to the trigger condition being met; using the adjustment signal on the suspension system; the first group of signals being signals related to a comfort braking control system and the second group of signals being signals related to driving expectations. A system for controlling a suspension system and a suspension control system are also disclosed.

Abstract: Provides are a display panel, a display module, and a display device. The display panel includes an opening region, a barrier region surrounding the opening region, a display region surrounding the barrier region, a base substrate, a crack blocking structure surrounding the opening region; a barrier wall surrounding the crack blocking structure. The barrier wall and the crack blocking structure include a first metal layer and a first organic layer, an edge of side of the first metal layer away from the base substrate is indented relative to an edge of side of the first organic layer proximal to the base substrate. The barrier wall and the crack blocking structure includes a deep groove penetrating through a film layer between the first organic layer and the base substrate, the deep groove surrounds the opening region. The first organic layer fills the deep groove and is connected to the base substrate.

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Abstract: A method and an apparatus for training a transferable vision transformer (TVT) for unsupervised domain adaption (UDA) in heterogeneous devices are provided. The method includes that a heterogeneous device including one or more graphic processing units (GPUs) loads multiple patches into the TVT which includes a transferability adaption module (TAM). Furthermore, a patch-level domain discriminator in the TAM assigns weights to the multiple patches and determines one or more transferable patches based on the weights. Moreover, the heterogeneous device generates a transferable attention output for an attention module in the TAM based on the one or more transferable patches.

Abstract: Embodiments are provided for building a configurable multilingual model. A computing system obtains a plurality of language-specific automatic speech recognition modules and a universal automatic speech recognition module trained on a multi-language training dataset comprising training data corresponding to each of the plurality of different languages. The computing system then compiles the universal automatic speech recognition module with the plurality of language-specific automatic speech recognition modules to generate a configurable multilingual model that is configured to selectively and dynamically utilize a sub-set of the plurality of language-specific automatic speech recognition modules with the universal automatic speech recognition module to process audio content in response to user input identifying one or more target languages associated with the audio content.

Abstract: The present disclosure provides a shift register unit, a gate driver circuit, and a display device, belonging to the field of display technology, which can solve the problem of unstable threshold voltage and current leakage of thin film transistors in existing shift register units. The shift register unit in the present disclosure includes: an input subcircuit, an output subcircuit, a pull-down control subcircuit, a pull-down subcircuit, a first noise reduction subcircuit, a first auxiliary control subcircuit, and a second auxiliary control subcircuit. The first auxiliary control subcircuit is configured to write the third reference level signal to the pull-down control node when the pull-down node is the first reference level signal, and control the pull-down subcircuit to be closed to control the first noise reduction subcircuit to be open.

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Abstract: The present disclosure relates to a method and system for pavement structural performance evaluation based on long-range laser vibration measurement. The method can more accurately evaluate the structural performance of the pavement by detecting the actual deflection value of the pavement during aircraft operation; By obtaining real-time deflection data of the airport runway, it is possible to detect changes in the structural performance of the airport runway in the long term without affecting the normal operation of the airport runway. The present invention has strong anti-interference ability, stable detection results, and can achieve non-contact, large-scale, and high-precision measurement of airport pavement deflection.

Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: The present invention disclosed an application of an antisense oligonucleotide targeting a PBX1 promoter region G-quadruplex in a preparation of a medicine for treating melanoma. The medicine for treating melanoma has one or more of following uses: inhibiting the proliferation of melanoma cell; inhibiting the migration of melanoma cell; inhibiting the invasion of melanoma cell; inhibiting the growth of melanoma; and inhibiting the lung metastasis of melanoma. The identification of the antisense oligonucleotide targeting the PBX1 promoter region G-quadruplex provided by the present invention provides a new drug target and new treatment methods and ideas for the development of a new generation of inhibiting melanoma medicines.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: Provided is an isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human CD40. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. An immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same are further provided.

Abstract: Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).